Please login to the form below

Darzalex

This page shows the latest Darzalex news and features for those working in and with pharma, biotech and healthcare.

and an anti-CD38 monoclonal antibody, such as Janssen’s Darzalex (daratumumab).

FDA hands BMS and bluebird bio a priority review for ide-cel

inhibitor and an anti-CD38 antibody, such as Janssen’s Darzalex (daratumumab).
Janssen scores another expansion for new Darzalex combination in the US

In the phase 3 CANDOR trial, researchers compared Darzalex, Kyprolis and dexamethasone to Kyprolis and dexamethasone alone in relapsed or refractory multiple myeloma patients. ... Janssen has been expanding the use of Darzalex with a number of
In virtual meeting, CHMP backs Sanofi’s myeloma drug Sarclisa

Sarclisa is the anti-CD38 drug to be approved after Johnson and Johnson’s Darzalex (daratumumab), which is already available across a range of multiple myeloma indications – including first-line use ... Darzalex was a $3bn product for J&J last year,
J&J’s bispecific lung cancer antibody nabs FDA breakthrough status

Janssen developed JNJ-6372 in collaboration with Genmab, which is also its collaborator on blockbuster multiple myeloma therapy Darzalex (daratumumab) and follow-up HexaBody-CD38.
BMS, AbbVie’s Empliciti flunks trial in first-line multiple myeloma

lagging behind rivals in the market such as Johnson &Johnson and Genmab’s CD38 inhibitor Darzalex (daratumumab). ... Meanwhile, as Darzalex has gone from strength to strength, other CD38-targeting drugs are coming through the late-stage pipeline to

More from news
Approximately 27 fully matching, plus 33 partially matching documents found.

European biotech: a new generation of leaders emerges

The latter is the platform used for a next-generation follow-up to Darzalex. ... If approved, this would become Genmab’s third product on the market, behind Darzalex and Novartis’ Arzerra.
Europe vs the US: New drug product approvals

Among the noteworthy orphan approvals are Exondys 51 (for the treatment of Duchenne muscular dystrophy, only approved in the US), Darzalex (for the treatment of multiple myeloma, approved in the US

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

If our patients are diverse, why are clinical trials so white?

One of these is Darzalex, another drug for multiple myeloma that is indicated across all lines of therapy. ... Darzalex is made by Janssen Oncology, a company under Johnson &Johnson.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Add my company

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?: The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.: Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....